Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
But BeOne canned its alcestobart deal in May.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
